Merck (MRK) Current Taxes (2009 - 2026)
Merck (MRK) posted quarterly Current Taxes of $3.9 billion for Q1 2026, down 23.84% YoY from $5.2 billion in Q1 2025, and down 16.5% sequentially from $4.7 billion in Q4 2025.
Merck (MRK) Current Taxes (2009 - 2026) Analysis & Trends
Merck has disclosed Current Taxes across 18 years of filings, most recently posting $3.9 billion for Q1 2026.
- In Q1 2026, Current Taxes fell 23.84% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $3.9 billion (down 23.84% YoY), while the FY2025 annual figure was $4.7 billion, up 20.75% from the prior year.
- Current Taxes eased to $3.9 billion in Q1 2026, from $4.7 billion in the prior quarter.
- Over the last five years, Current Taxes for MRK reached as high as $5.2 billion in Q1 2025 and fell as low as $1.4 billion in Q2 2022.
- The 5-year median for Current Taxes is $2.6 billion (2023), against an average of $3.0 billion.
- Annual changes were most pronounced in 2024 — Current Taxes jumped 118.58% — and 2026, when it slipped 23.84%.
- A 5-year view of Current Taxes shows it stood at $2.0 billion in 2022, then jumped by 33.38% to $2.6 billion in 2023, then surged by 47.75% to $3.9 billion in 2024, then gained by 20.75% to $4.7 billion in 2025, then slipped by 16.5% to $3.9 billion in 2026.
- According to Business Quant data, Current Taxes over the past three periods registered $3.9 billion, $4.7 billion, and $4.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.09 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.30 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 3.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 3.13 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 93.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.95 Bn |
| Dec 31, 2025 | 4.73 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.16 Bn |
| Mar 31, 2025 | 5.18 Bn |
| Dec 31, 2024 | 3.91 Bn |
| Sep 30, 2024 | 4.33 Bn |
| Jun 30, 2024 | 2.78 Bn |
| Mar 31, 2024 | 2.40 Bn |
| Dec 31, 2023 | 2.65 Bn |
| Sep 30, 2023 | 1.98 Bn |
| Jun 30, 2023 | 1.49 Bn |
| Mar 31, 2023 | 1.87 Bn |
| Dec 31, 2022 | 1.99 Bn |
| Sep 30, 2022 | 1.70 Bn |
| Jun 30, 2022 | 1.44 Bn |
| Mar 31, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.22 Bn |
| Sep 30, 2021 | 954.00 Mn |
| Jun 30, 2021 | 971.00 Mn |